Medical; Abortion, Fetus Clinical Trial
Official title:
Feasibility of Home Follow-up After Medication Abortion (MAB)
NCT number | NCT04304365 |
Other study ID # | H-39499 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2020 |
Est. completion date | May 2021 |
Verified date | October 2020 |
Source | Boston Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to evaluate a home follow-up alternative after medication abortion with pregnancy testing and a completion test. Clinical evaluation after a medication abortion (MAB) is standard of care to diagnose continued pregnancy and treat complications, typically done with a provider and an ultrasound examination or serial blood testing. Follow-up rates in the literature after MAB have been found to be 51% to 77% in recent literature using these standard follow-up methods. Though medication abortion is highly efficient, the on-going pregnancy rate is about 4% for pregnancies with gestational age up to 70 days from last menstrual period, thus highlighting the importance of follow-up as patients may not know they have a continued pregnancy weeks to even months after taking medication for an abortion. The investigators plan on providing participants with the option of a home follow-up option versus the standard of care (clinic) option. The primary objective of this study is looking at follow-up rates by each of these groups. As more options are provided for follow-up to patients, it is hoped that follow-up rates will improve and reduce the burdens of clinic visits on both providers and patients, ultimately making continued pregnancy after a medication abortion a never event.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 2021 |
Est. primary completion date | May 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - English or Spanish speakers - Have a working phone they consider their own with text messaging capabilities - Have a viable intrauterine pregnancy - Are eligible for a medication abortion (10 weeks gestational age or less) - Elect the method of medication abortion Exclusion Criteria: -None |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Boston Medical Center | Society of Family Planning |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Completed follow-up for the clinic group | Percent of participants in this group that return to the scheduled clinic visit | 2 weeks | |
Primary | Completed follow-up for the home group | Percent of participants in this group that completed the final texted survey | 2 weeks | |
Secondary | Any follow up | Number of participants who had any follow-up based on unscheduled clinic visits | 42 days | |
Secondary | Ongoing pregnancy | Number of participants found to have an ongoing pregnancy after a medication abortion | 42 days | |
Secondary | Complications after the medical abortion | Number of participants presenting with complications such need for transfusion and treatment of a uterine infection | 42 days | |
Secondary | Number of emergency visits | Number of participants presenting to the emergency room | 42 days | |
Secondary | Acceptability of chosen follow-up | An investigator developed survey will document acceptability of the follow-up process, given at the follow-up visit | 2 weeks | |
Secondary | Screen positive for pregnancy in the home follow-up group | The percentage of participants that screen positive from a urine test using LSPT in the home follow-up group, requiring a clinic follow-up visit | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02694198 -
Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion
|
N/A | |
Completed |
NCT01860521 -
Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Termination of Pregnancy Analgesia
|
N/A | |
Completed |
NCT03400358 -
Uterocervical Angle in the Pregnancy Termination of Multiparous Women
|
N/A | |
Recruiting |
NCT05342467 -
Gemeprost Versus Dinoprostone in First Trimester Miscarriages
|
Phase 2 | |
Recruiting |
NCT03269279 -
Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso
|
Phase 3 | |
Completed |
NCT02381223 -
Simplified Medical Abortion Screening: A Pilot Demonstration Project
|
N/A | |
Recruiting |
NCT05940233 -
Comparison of Rate of Complete Abortion Between Letrozole Plus Misoprostol vs Misoprostol Alone
|
N/A | |
Not yet recruiting |
NCT03570307 -
Fertility and Obstetric Outcomes After Medical Management Versus Surgical Treatment for First-trimester Miscarriage First-trimester Miscarriage
|
N/A | |
Completed |
NCT01943279 -
Comparison of Telephone Follow-up With In-person Follow-up After Medical Abortion
|
N/A | |
Not yet recruiting |
NCT04194658 -
Effectiveness of Pretreatment Letrozole Versus Misoprostol Alone in Missed Abortion
|
Phase 2 | |
Completed |
NCT03194126 -
Evaluation of Efficacy of Two Therapeutic Strategies for Cervical Maturation Before Medical Termination
|
N/A | |
Completed |
NCT01966874 -
Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days Gestation
|
Phase 2/Phase 3 |